-
1 Comment
OraSure Technologies, Inc is currently in a long term downtrend where the price is trading 12.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
OraSure Technologies, Inc's total revenue rose by 26.6% to $63M since the same quarter in the previous year.
Its net income has dropped by 23.7% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 395.6% to $-12M since the same quarter in the previous year.
Based on the above factors, OraSure Technologies, Inc gets an overall score of 2/5.
ISIN | US68554V1089 |
---|---|
Exchange | NASDAQ |
CurrencyCode | USD |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Market Cap | 232M |
---|---|
PE Ratio | None |
Target Price | 5 |
Beta | 0.77 |
Dividend Yield | None |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OSUR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025